In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota.
Here are the key trials we discussed:
1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation.
pubmed.ncbi.nlm.nih.gov/30824...
2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis
pubmed.ncbi.nlm.nih.gov/37342...
3. Patient-Reported Outcomes of BMT CTN 1703
ash.confex.com/ash/2023/webpr...
4. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
pubmed.ncbi.nlm.nih.gov/37311...
5. BMT CTN 1301 trial: Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
pubmed.ncbi.nlm.nih.gov/34855...
6. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD (ABA2)
pubmed.ncbi.nlm.nih.gov/33449...
7. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus
ash.confex.com/ash/2023/webpr...
30 янв 2024
